Industry News

Laboratory Heads from Major Academic Medical Centers Urge OMB Not to Release FDA Guidance on the Regulation of LDTs.
Can PGXL Informatics Make Drugs Safer and More Effective?
FDA Accepts Sanofi's New Drug Application for Basal Insulin Toujeo Sanofi
DHL launches new logistics service for life sciences products handled at extremely low temperatures
Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
Medivir: U.S. FDA Has Granted Priority Review for OLYSIO in Combination with sofosbuvir Supplementary New Drug Application
GLENMARK TO LAUNCH ANTI-HYPERTENSION DRUG IN US
FDA Notifies Not to Use Gold Vigra and Miraculous Evil Root: AttorneyOne Monitor and Keep Consumers Informed
Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application
FDA Designates Opioid Overdose Treatment for Fast Track Development Program
Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan
Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan
Actavis Seeks FDA Approval to Market Dalfampridine Extended-Release Tablets
Shire ties knot after AbbVie lifts offer
Actavis Confirms Generic Diclegis Patent Challenge
Dr. Reddy's Introduces Duloxetine Delayed-Release Capsules USP in U.S. Market
Flamel Technologies Gets OK from FDA for Vazculep
Vernalis PLC and Tri Pharma Submit Application to FDA for TuzistraTM XR
SteriWeb Medical Gets FDA OTC Clearance for Omnicide Antimicrobial Gel
US drugmaker AbbVie in pounds 30bn talks to take over British rival Shire: Move echoes Pfizer's failed bid to buy up AstraZeneca Deal would cut American firm's tax from 22% to 13%
Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application
Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application
Actavis Confirms Generic Diclegis� Patent Challenge
Orphan Drug Approvals Have Increased, But High Costs Pose Challenges for Patients, According to the Tufts Center for the Study of Drug Development
723 deaths due to lack of snake anti-venom